medmix AG
medmix AG (MEDX.SW) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for medmix AG (MEDX.SW), featuring income statements, balance sheets, and cash flow data.
medmix AG (MEDX.SW) Income Statement & Financial Overview
Explore comprehensive income reports for medmix AG MEDX.SW, broken down by year and quarter.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $242.70M | $241.20M | $238.50M | $119.25M |
| Cost of Revenue | $163.60M | $160.60M | $162.80M | $81.40M |
| Gross Profit | $79.10M | $80.60M | $75.70M | $37.85M |
| Gross Profit Ratio | $0.33 | $0.33 | $0.32 | $0.32 |
| R&D Expenses | $11.70M | $13.70M | $12.80M | $6.80M |
| SG&A Expenses | $62.70M | $53.70M | $61.80M | $30.90M |
| Operating Expenses | $74.40M | $67.70M | $74.60M | $38.50M |
| Total Costs & Expenses | -$238.00M | $228.30M | $237.40M | $119.90M |
| Interest Income | $300000.00 | $1.00M | $1.00M | $2.40M |
| Interest Expense | $5.60M | $12.40M | $5.90M | $0.00 |
| Depreciation & Amortization | $27.40M | $29.00M | $32.80M | $8.95M |
| EBITDA | $25.70M | $43.00M | $32.70M | $10.25M |
| EBITDA Ratio | $0.11 | $0.18 | $0.14 | $0.09 |
| Operating Income | $4.70M | $12.90M | $1.10M | $1.30M |
| Operating Income Ratio | $0.02 | $0.05 | $0.005 | $0.01 |
| Other Income/Expenses (Net) | -$12.00M | -$6.30M | -$7.20M | -$3.80M |
| Income Before Tax | -$7.30M | $6.60M | -$6.10M | -$3.05M |
| Income Before Tax Ratio | -$0.03 | $0.03 | -$0.03 | -$0.03 |
| Income Tax Expense | -$1.00M | $1.00M | $500000.00 | $250000.00 |
| Net Income | -$12.60M | $5.20M | -$7.00M | -$3.50M |
| Net Income Ratio | -$0.05 | $0.02 | -$0.03 | -$0.03 |
| EPS | -$0.31 | $0.12 | -$0.17 | -$0.09 |
| Diluted EPS | -$0.31 | $0.12 | -$0.17 | -$0.09 |
| Weighted Avg Shares Outstanding | $40.79M | $43.33M | $40.78M | $41.18M |
| Weighted Avg Shares Outstanding (Diluted) | $40.79M | $43.33M | $40.78M | $41.18M |
Financial performance has remained strong, with revenue growing from $119.25M in Q3 2023 to $242.70M in Q4 2024. Gross profit continued to perform well, with margins at 33% in the latest quarter. Operating income reached $4.70M in Q4 2024, holding a steady 2% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $25.70M. Net income dropped to -$12.60M, keeping EPS at -$0.31. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan